Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study

Proton pump inhibitor (PPI) use has been associated with hypomagnesemia in case reports and hospital-based cohort studies. Our objective was to determine whether PPI use is associated with hypomagnesemia in the general population and whether this is also found in histamine 2 receptor antagonist (H2R...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	American journal of kidney diseases Ročník 66; číslo 5; s. 775
Hlavní autoři:	Kieboom, Brenda C T, Kiefte-de Jong, Jessica C, Eijgelsheim, Mark, Franco, Oscar H, Kuipers, Ernst J, Hofman, Albert, Zietse, Robert, Stricker, Bruno H, Hoorn, Ewout J
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.11.2015
Témata:	Cohort Studies Cross-Sectional Studies Diet - statistics & numerical data Histamine H2 Antagonists - therapeutic use Linear Models Magnesium - blood Multivariate Analysis Prospective Studies Proton Pump Inhibitors - therapeutic use Risk Factors Sodium Potassium Chloride Symporter Inhibitors - therapeutic use Water-Electrolyte Imbalance - epidemiology histamine 2 receptor antagonist (H2RA) diuretics acid-suppressive medication drug safety Rotterdam Study hypomagnesemia intestinal magnesium loss magnesium proton pump inhibitor (PPI) population-based cohort Epidemiology TRPM6
ISSN:	1523-6838, 1523-6838
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Proton pump inhibitor (PPI) use has been associated with hypomagnesemia in case reports and hospital-based cohort studies. Our objective was to determine whether PPI use is associated with hypomagnesemia in the general population and whether this is also found in histamine 2 receptor antagonist (H2RA) users. Prospective cohort study. 9,818 individuals from the general population (Rotterdam Study). PPI use and H2RA use compared to no use. Serum magnesium and hypomagnesemia (serum magnesium ≤ 1.44 mEq/L). Analyses were adjusted for age, sex, body mass index, kidney function, comorbid conditions, and alcohol and diuretic use. Serum magnesium level was 0.022 mEq/L lower in PPI users (n=724; 95% CI, -0.032 to -0.014 mEq/L) versus those with no use. PPI use was associated with increased risk of hypomagnesemia (n=36; OR, 2.00; 95% CI, 1.36-2.93) compared to no use. Effect modification was found between the use of PPIs and loop diuretics; in participants using loop diuretics (n=270), PPI use was associated with a further increased risk of hypomagnesemia (n=5; OR, 7.22; 95% CI, 1.69-30.83) compared to no use. The increased risk with PPIs was only seen after prolonged use (range, 182-2,618 days; OR, 2.99; 95% CI, 1.73-5.15). Including dietary magnesium intake into the model did not alter results (available for 2,504 participants, including 231 PPI users). H2RA users (n=250) also had a lower serum magnesium level (-0.016 [95% CI, -0.032 to -0.002] mEq/L) and increased risk of hypomagnesemia (n=12; OR, 2.00; 95% CI, 1.08-3.72) compared to those with no use, but no interaction with loop diuretics. Cross-sectional analysis with single serum magnesium measurement. PPI use is associated with hypomagnesemia in the general population. Prolonged PPI use and concomitant loop diuretic use are associated with a stronger risk increase. Similar but weaker associations were found in H2RA users, except for interaction with loop diuretics.
AbstractList	Proton pump inhibitor (PPI) use has been associated with hypomagnesemia in case reports and hospital-based cohort studies. Our objective was to determine whether PPI use is associated with hypomagnesemia in the general population and whether this is also found in histamine 2 receptor antagonist (H2RA) users.BACKGROUNDProton pump inhibitor (PPI) use has been associated with hypomagnesemia in case reports and hospital-based cohort studies. Our objective was to determine whether PPI use is associated with hypomagnesemia in the general population and whether this is also found in histamine 2 receptor antagonist (H2RA) users.Prospective cohort study.STUDY DESIGNProspective cohort study.9,818 individuals from the general population (Rotterdam Study).SETTING & PARTICIPANTS9,818 individuals from the general population (Rotterdam Study).PPI use and H2RA use compared to no use.PREDICTORPPI use and H2RA use compared to no use.Serum magnesium and hypomagnesemia (serum magnesium ≤ 1.44 mEq/L). Analyses were adjusted for age, sex, body mass index, kidney function, comorbid conditions, and alcohol and diuretic use.OUTCOMES & MEASUREMENTSSerum magnesium and hypomagnesemia (serum magnesium ≤ 1.44 mEq/L). Analyses were adjusted for age, sex, body mass index, kidney function, comorbid conditions, and alcohol and diuretic use.Serum magnesium level was 0.022 mEq/L lower in PPI users (n=724; 95% CI, -0.032 to -0.014 mEq/L) versus those with no use. PPI use was associated with increased risk of hypomagnesemia (n=36; OR, 2.00; 95% CI, 1.36-2.93) compared to no use. Effect modification was found between the use of PPIs and loop diuretics; in participants using loop diuretics (n=270), PPI use was associated with a further increased risk of hypomagnesemia (n=5; OR, 7.22; 95% CI, 1.69-30.83) compared to no use. The increased risk with PPIs was only seen after prolonged use (range, 182-2,618 days; OR, 2.99; 95% CI, 1.73-5.15). Including dietary magnesium intake into the model did not alter results (available for 2,504 participants, including 231 PPI users). H2RA users (n=250) also had a lower serum magnesium level (-0.016 [95% CI, -0.032 to -0.002] mEq/L) and increased risk of hypomagnesemia (n=12; OR, 2.00; 95% CI, 1.08-3.72) compared to those with no use, but no interaction with loop diuretics.RESULTSSerum magnesium level was 0.022 mEq/L lower in PPI users (n=724; 95% CI, -0.032 to -0.014 mEq/L) versus those with no use. PPI use was associated with increased risk of hypomagnesemia (n=36; OR, 2.00; 95% CI, 1.36-2.93) compared to no use. Effect modification was found between the use of PPIs and loop diuretics; in participants using loop diuretics (n=270), PPI use was associated with a further increased risk of hypomagnesemia (n=5; OR, 7.22; 95% CI, 1.69-30.83) compared to no use. The increased risk with PPIs was only seen after prolonged use (range, 182-2,618 days; OR, 2.99; 95% CI, 1.73-5.15). Including dietary magnesium intake into the model did not alter results (available for 2,504 participants, including 231 PPI users). H2RA users (n=250) also had a lower serum magnesium level (-0.016 [95% CI, -0.032 to -0.002] mEq/L) and increased risk of hypomagnesemia (n=12; OR, 2.00; 95% CI, 1.08-3.72) compared to those with no use, but no interaction with loop diuretics.Cross-sectional analysis with single serum magnesium measurement.LIMITATIONSCross-sectional analysis with single serum magnesium measurement.PPI use is associated with hypomagnesemia in the general population. Prolonged PPI use and concomitant loop diuretic use are associated with a stronger risk increase. Similar but weaker associations were found in H2RA users, except for interaction with loop diuretics.CONCLUSIONSPPI use is associated with hypomagnesemia in the general population. Prolonged PPI use and concomitant loop diuretic use are associated with a stronger risk increase. Similar but weaker associations were found in H2RA users, except for interaction with loop diuretics. Proton pump inhibitor (PPI) use has been associated with hypomagnesemia in case reports and hospital-based cohort studies. Our objective was to determine whether PPI use is associated with hypomagnesemia in the general population and whether this is also found in histamine 2 receptor antagonist (H2RA) users. Prospective cohort study. 9,818 individuals from the general population (Rotterdam Study). PPI use and H2RA use compared to no use. Serum magnesium and hypomagnesemia (serum magnesium ≤ 1.44 mEq/L). Analyses were adjusted for age, sex, body mass index, kidney function, comorbid conditions, and alcohol and diuretic use. Serum magnesium level was 0.022 mEq/L lower in PPI users (n=724; 95% CI, -0.032 to -0.014 mEq/L) versus those with no use. PPI use was associated with increased risk of hypomagnesemia (n=36; OR, 2.00; 95% CI, 1.36-2.93) compared to no use. Effect modification was found between the use of PPIs and loop diuretics; in participants using loop diuretics (n=270), PPI use was associated with a further increased risk of hypomagnesemia (n=5; OR, 7.22; 95% CI, 1.69-30.83) compared to no use. The increased risk with PPIs was only seen after prolonged use (range, 182-2,618 days; OR, 2.99; 95% CI, 1.73-5.15). Including dietary magnesium intake into the model did not alter results (available for 2,504 participants, including 231 PPI users). H2RA users (n=250) also had a lower serum magnesium level (-0.016 [95% CI, -0.032 to -0.002] mEq/L) and increased risk of hypomagnesemia (n=12; OR, 2.00; 95% CI, 1.08-3.72) compared to those with no use, but no interaction with loop diuretics. Cross-sectional analysis with single serum magnesium measurement. PPI use is associated with hypomagnesemia in the general population. Prolonged PPI use and concomitant loop diuretic use are associated with a stronger risk increase. Similar but weaker associations were found in H2RA users, except for interaction with loop diuretics.
Author	Hofman, Albert Franco, Oscar H Zietse, Robert Hoorn, Ewout J Kieboom, Brenda C T Eijgelsheim, Mark Kiefte-de Jong, Jessica C Stricker, Bruno H Kuipers, Ernst J
Author_xml	– sequence: 1 givenname: Brenda C T surname: Kieboom fullname: Kieboom, Brenda C T organization: Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands; Inspectorate of Health Care, Utrecht, the Netherlands – sequence: 2 givenname: Jessica C surname: Kiefte-de Jong fullname: Kiefte-de Jong, Jessica C organization: Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands; Leiden University College, The Hague, the Netherlands – sequence: 3 givenname: Mark surname: Eijgelsheim fullname: Eijgelsheim, Mark organization: Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands – sequence: 4 givenname: Oscar H surname: Franco fullname: Franco, Oscar H organization: Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands – sequence: 5 givenname: Ernst J surname: Kuipers fullname: Kuipers, Ernst J organization: Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands – sequence: 6 givenname: Albert surname: Hofman fullname: Hofman, Albert organization: Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands – sequence: 7 givenname: Robert surname: Zietse fullname: Zietse, Robert organization: Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands – sequence: 8 givenname: Bruno H surname: Stricker fullname: Stricker, Bruno H email: b.stricker@erasmusmc.nl organization: Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands; Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands; Inspectorate of Health Care, Utrecht, the Netherlands. Electronic address: b.stricker@erasmusmc.nl – sequence: 9 givenname: Ewout J surname: Hoorn fullname: Hoorn, Ewout J organization: Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/26123862$$D View this record in MEDLINE/PubMed
BookMark	eNpNUEtLw0AYXKRiH_oHPMgevSTufmk2G29S6gMKetBz-PbRJjXZjdnNof_eghUKAzPDDHOYOZk47ywht5ylnOXZwz7F_bdJgfE8ZUdwuCAznkOWCJnJyZmeknkIe8ZYmQlxRaYgOGRSwIyYj8FH72g_dj1tXN2oJvohUHSG1ofed7hzNtiuwWNKY23pzjo7YEt7348txsa7R4pnLlEYrKHa136INMTRHK7J5RbbYG9OvCBfz-vP1WuyeX95Wz1tEi2WEBO1zQ1DQJ1JhUyCRq74UjIGujQ5GM4zgUXONTcagTFprQJRFrY0WDC1hQW5_9vtB_8z2hCrrgnati0668dQ8QKKUhYiXx6rd6fqqDprqn5oOhwO1f8z8Avle2pG
CitedBy_id	crossref_primary_10_1016_j_pan_2020_12_002 crossref_primary_10_1093_ndt_gfw073 crossref_primary_10_1016_j_lmd_2024_100027 crossref_primary_10_1093_nutrit_nuw018 crossref_primary_10_1186_s12902_021_00838_y crossref_primary_10_1177_1098612X231201769 crossref_primary_10_1186_s12877_021_02715_8 crossref_primary_10_1097_MCG_0000000000001420 crossref_primary_10_1111_ijpp_12537 crossref_primary_10_1186_s12916_017_0804_x crossref_primary_10_1016_j_jbspin_2024_105714 crossref_primary_10_1002_ohn_1140 crossref_primary_10_1016_j_ijcard_2016_01_110 crossref_primary_10_1080_17843286_2018_1516173 crossref_primary_10_1080_19390211_2020_1834050 crossref_primary_10_1016_j_ijsu_2017_01_085 crossref_primary_10_1097_MD_0000000000017788 crossref_primary_10_1542_peds_2018_0333G crossref_primary_10_1007_s11255_020_02525_8 crossref_primary_10_1186_s12883_025_04334_x crossref_primary_10_1016_j_ejim_2016_01_026 crossref_primary_10_7759_cureus_64044 crossref_primary_10_1002_pds_4636 crossref_primary_10_2215_CJN_02190218 crossref_primary_10_1371_journal_pmed_1003140 crossref_primary_10_1681_ASN_2015121377 crossref_primary_10_1016_j_clinthera_2016_03_024 crossref_primary_10_3390_ijms20205128 crossref_primary_10_1016_j_urology_2024_09_015 crossref_primary_10_1159_000510163 crossref_primary_10_3390_jcm8122162 crossref_primary_10_1097_MCG_0000000000001035 crossref_primary_10_1016_j_jvoice_2020_01_018 crossref_primary_10_1177_0897190017738917 crossref_primary_10_3109_00365521_2016_1141317 crossref_primary_10_3945_an_115_008631 crossref_primary_10_1001_jama_2020_18400 crossref_primary_10_1016_j_krcp_2016_04_002 crossref_primary_10_3390_nu17050887 crossref_primary_10_1001_jama_2020_17672 crossref_primary_10_1007_s00424_024_03017_9 crossref_primary_10_1080_14796678_2024_2412910 crossref_primary_10_3390_pharma4030015 crossref_primary_10_1007_s12325_020_01271_8 crossref_primary_10_1111_bcp_15182 crossref_primary_10_3390_jcm12062262 crossref_primary_10_1186_s40780_022_00266_7 crossref_primary_10_1016_j_clnu_2018_11_018 crossref_primary_10_1093_sleep_zsac018 crossref_primary_10_1097_MOG_0000000000000504 crossref_primary_10_1371_journal_pone_0228938 crossref_primary_10_1002_acr_24876 crossref_primary_10_1136_bmjopen_2016_015735 crossref_primary_10_1097_IMNA_D_22_00027 crossref_primary_10_1177_0018578717747192 crossref_primary_10_1053_j_ackd_2018_01_005 crossref_primary_10_3389_fphar_2023_1092476 crossref_primary_10_1017_S0029665121000926 crossref_primary_10_1186_s12882_023_03300_4 crossref_primary_10_1002_prp2_829 crossref_primary_10_1097_FPC_0000000000000259 crossref_primary_10_1177_2042098618809927 crossref_primary_10_1212_CPJ_0000000000200302 crossref_primary_10_1111_sdi_12573 crossref_primary_10_1111_apha_13846 crossref_primary_10_7759_cureus_55856 crossref_primary_10_1097_MEG_0000000000001198 crossref_primary_10_1007_s10654_017_0321_4 crossref_primary_10_5847_wjem_j_1920_8642_2023_104 crossref_primary_10_3390_ijms17040454 crossref_primary_10_1093_nutrit_nuy002 crossref_primary_10_7759_cureus_27188 crossref_primary_10_1007_s00228_021_03237_3 crossref_primary_10_1016_j_joca_2021_12_010 crossref_primary_10_3748_wjg_v23_i37_6907 crossref_primary_10_1038_s41598_023_48430_9 crossref_primary_10_3390_jcm11144015 crossref_primary_10_57187_s_4072 crossref_primary_10_3390_ph17081082 crossref_primary_10_1053_j_ajkd_2019_07_012 crossref_primary_10_3390_nu10050546 crossref_primary_10_1016_j_rhum_2025_04_008 crossref_primary_10_1097_MD_0000000000015011 crossref_primary_10_1007_s00125_017_4224_4 crossref_primary_10_1016_j_tcm_2018_10_008 crossref_primary_10_2215_CJN_12991216 crossref_primary_10_1007_s11010_023_04921_x crossref_primary_10_1016_j_revmed_2025_06_016 crossref_primary_10_70749_ijbr_v3i3_913 crossref_primary_10_1111_jgh_14671 crossref_primary_10_1177_09612033221149884
ContentType	Journal Article
Copyright	Copyright © 2015 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Copyright_xml	– notice: Copyright © 2015 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1053/j.ajkd.2015.05.012
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1523-6838
ExternalDocumentID	26123862
Genre	Research Support, Non-U.S. Gov't Journal Article Comparative Study
GroupedDBID	--- --K .1- .55 .FO .GJ 0R~ 1B1 1P~ 23M 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 AAEDT AAEDW AALRI AAQFI AAQQT AAQXK AAWTL AAXUO AAYOK ABCQX ABFRF ABJNI ABLJU ABMAC ABOCM ABWVN ACGFO ACGFS ACRPL ADBBV ADMUD ADNMO ADPAM ADVLN AEFWE AENEX AEVXI AFCTW AFFNX AFJKZ AFRHN AFTJW AGHFR AITUG AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ ASPBG AVWKF AZFZN BELOY CAG CGR COF CS3 CUY CVF EBS ECM EFJIC EIF EJD EX3 F5P FDB FEDTE FGOYB GBLVA HVGLF HZ~ J5H K-O KOM L7B M41 MO0 N4W NPM O9- OE- P2P PC. PI~ R2- ROL SEL SES SJN SSZ TWZ UNMZH WOW X7M XH2 YCW Z5R ZGI ZXP 7X8 AAFWJ ACVFH ADCNI EFKBS
ID	FETCH-LOGICAL-c642t-bf5d0a2ac38ba082ca1b148002c9d52d1136a751c1dca2008eeb2697e9da70bf2
IEDL.DBID	7X8
ISICitedReferencesCount	108
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000363489600017&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1523-6838
IngestDate	Sat Sep 27 18:16:45 EDT 2025 Thu Jan 02 22:38:19 EST 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	5
Keywords	histamine 2 receptor antagonist (H2RA) diuretics acid-suppressive medication drug safety Rotterdam Study hypomagnesemia intestinal magnesium loss magnesium proton pump inhibitor (PPI) population-based cohort Epidemiology TRPM6
Language	English
License	Copyright © 2015 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c642t-bf5d0a2ac38ba082ca1b148002c9d52d1136a751c1dca2008eeb2697e9da70bf2
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23
OpenAccessLink	http://www.ajkd.org/article/S0272638615008367/pdf
PMID	26123862
PQID	1727987654
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_1727987654 pubmed_primary_26123862
PublicationCentury	2000
PublicationDate	2015-11-01
PublicationDateYYYYMMDD	2015-11-01
PublicationDate_xml	– month: 11 year: 2015 text: 2015-11-01 day: 01
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	American journal of kidney diseases
PublicationTitleAlternate	Am J Kidney Dis
PublicationYear	2015
SSID	ssj0009366
Score	2.5200806
Snippet	Proton pump inhibitor (PPI) use has been associated with hypomagnesemia in case reports and hospital-based cohort studies. Our objective was to determine...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	775
SubjectTerms	Cohort Studies Cross-Sectional Studies Diet - statistics & numerical data Histamine H2 Antagonists - therapeutic use Linear Models Magnesium - blood Multivariate Analysis Prospective Studies Proton Pump Inhibitors - therapeutic use Risk Factors Sodium Potassium Chloride Symporter Inhibitors - therapeutic use Water-Electrolyte Imbalance - epidemiology
Title	Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study
URI	https://www.ncbi.nlm.nih.gov/pubmed/26123862 https://www.proquest.com/docview/1727987654
Volume	66
WOSCitedRecordID	wos000363489600017&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7Uinjx_agvVvC6tpvN5uFFRCxeWnpQ6K1M9lFTaRLbKvjvnU1S60UQvASWEFh2JjPf7Ox-HyFXxtMisOCzxOqI-TE3LLISmJDWDwCczEklNhH2etFgEPfrDbdZfaxyERPLQK1z5fbIWy7RYn0cSP-2eGNONcp1V2sJjVXSEAhlnFeHgyVbeCzKXiWmKMGCSET1pRn0u9b4GsavjimUy4q50_sdYpapprP930nukK0aZNK7yit2yYrJ9shGt26j7xPdn-aI-WiBtqRp9pImqRPdoZBp-vJZ5BMYOWHKSQr4liJEpKOKnZoW33pfNxR-jJjLhpo6ud3pnJactQfkufPwdP_IarkFprAImaO1pG6DB0pECSAyUMATLJYwZKpYS0879RcIJVdcK3DHJgxW5UEcmlhD2E6sd0jWsjwzx4QqG2PwMGATDr5tAwDnSnJQNioZx5rkcrF-Q3Rn16OAzOTvs-FyBZvkqDLCsKh4N4aO7UxgBXbyh69PyaazbXVr8Iw0LP7M5pysq495OptelH6Cz16_-wXYF8ot
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Proton+pump+inhibitors+and+hypomagnesemia+in+the+general+population%3A+a+population-based+cohort+study&rft.jtitle=American+journal+of+kidney+diseases&rft.au=Kieboom%2C+Brenda+C+T&rft.au=Kiefte-de+Jong%2C+Jessica+C&rft.au=Eijgelsheim%2C+Mark&rft.au=Franco%2C+Oscar+H&rft.date=2015-11-01&rft.eissn=1523-6838&rft.volume=66&rft.issue=5&rft.spage=775&rft_id=info:doi/10.1053%2Fj.ajkd.2015.05.012&rft_id=info%3Apmid%2F26123862&rft_id=info%3Apmid%2F26123862&rft.externalDocID=26123862
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1523-6838&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1523-6838&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1523-6838&client=summon